Brainstorm Cell Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.8M
- Price
- $0.98
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.55%
- Volume
- 51.5K
About
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Quick stats
Shares outstanding11.0M
Computed float10.2M
Float / shares92.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001137883
AI Summary
AI-generated1/6
majorbearishearnings
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm reported Q2 cash of only $0.2 million, down from $1.03 million a year ago, with net losses widening to $3.9 million from $2.9 million.
The company is advancing its Phase 3b ENDURANCE trial of NurOwn for ALS under a Special Protocol Assessment and appointed former FDA official Peter J. Pitts as Executive Chairman.
First-half 2026 capital raises totaled approximately $2.4 million including a $400,000 private placement in May, against an $11.6 million accumulated deficit and $12.4 million in total liabilities.
Red flags
- cash position depleted to $0.2 million
- stockholders' deficit of $11.6 million
- liabilities ($12.4M) exceed assets ($0.8M) - significant going concern risk
- net losses widened to $3.9M from $2.9M year ago
- only $2.4M raised in first half 2026 against ongoing burn of ~$3.9M in Q2